Clinical Trial Update: PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for PROlectin M, an antagonist targeting nucleocapsid terminal region, in COVID-19; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Respiratory Infection
• Cytokine Release Syndrome

Drugs mentioned

• PROlectin M

Snippet

Sponsor: Bioxytran Inc. | Conditions: COVID-19, COVID-19 Pandemic | Phase 3 | Status: UNKNOWN